89bio To Be Bought By Roche For Around $3.5 Bln

Roche Holding AG has agreed to acquire 89bio, Inc. for $14.50 per share in cash, totaling $2.4 billion, representing a 79% premium to 89bio's September 17 closing price. The deal includes an additional contingent value right of up to $6 per share, potentially raising the total equity value to $3.5 billion or $20.50 per share. This transaction, expected to close in Q4 2025 via a tender offer, will integrate 89bio's liver and cardiometabolic disease therapies into Roche's pharmaceuticals division, leveraging Roche's global development and commercialization capabilities.

Analysis

Roche Holding AG has agreed to acquire 89bio, Inc. in a deal structured to deliver significant upfront value and potential long-term upside to 89bio shareholders. The transaction includes a cash payment of $14.50 per share, representing a substantial 79% premium to 89bio's closing price on September 17. The deal also features a non-tradeable contingent value right (CVR) of up to an additional $6 per share, which could increase the total transaction value from $2.4 billion to approximately $3.5 billion. The strategic rationale for Roche is to integrate 89bio's therapies, specifically the promising pegozafermin for liver and cardiometabolic diseases, into its global pharmaceuticals division, leveraging its established development and commercialization capabilities. However, the projected closing date in the fourth quarter of 2025 is unusually distant for a transaction of this nature, suggesting that both parties anticipate a lengthy and potentially complex regulatory review process, which introduces a significant element of time-based and execution risk.

Key Decisions for Investors

• Investors in 89bio (ETNB) should weigh the certainty of the significant 79% premium against the considerable timeline risk, as the extended Q4 2025 closing date exposes the deal to potential regulatory hurdles and market volatility.
• The potential for an additional $6 per share via the contingent value right represents a substantial but uncertain component of the deal's total value, and its realization is dependent on future milestones that carry inherent clinical and regulatory risk.
• For Roche (RHHBY) investors, this is a strategic pipeline acquisition, but they should monitor for any adverse developments during the protracted regulatory process that could impact the final cost and synergies of the integration.